Other therapeutic approaches may be developed to take advantage of these findings in the treatment of human breast cancer, including the development of inhibitors of C35 interaction with proteins other than Syk, such as the novel ITAM-interacting protein Shb (Matskova et al, 2007). This evidence concerns the gene SHB and breast carcinoma.